TrialJournal of the American Heart Association2021

Benefit-Risk of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness: Pooled Analysis From MAGELLAN and MARINER.

Gary E Raskob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.